Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study
Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML,
Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF.
Harper Hospital and Karmanos Cancer Institute, Detroit, MI, USA.
Eur J Pain. 1998;2(3):239-49


Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled-release oxycodone ( [Formula: see text] ) or controlled-release morphine ( [Formula: see text] ) every 12 h for up to 12 days. Stable analgesia was achieved by 83% of controlled-release oxycodone and 81% of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3=severe) decreased from baseline within each group ( [Formula: see text] ), from 1.9 (0.1) to 1.3 (0.1), mean (SE), with controlled-release oxycodone, and from 1.6 (0.1) to 1.0 (0.1) with controlled-release morphine (no significant between-group differences). Typical opioid adverse experiences were reported in both groups. Hallucinations were reported only with controlled-release morphine ( [Formula: see text] ). Visual analog scores (VAS) for 'itchy' and 'scratchin' were lower with controlled-release oxycodone ( [Formula: see text] ), as was peak-to-trough fluctuation in steady-state plasma concentration ( [Formula: see text] ). The correlation between plasma concentration and dose was stronger ( [Formula: see text] ) for oxycodone (0.7) than morphine (0.3). The relationship between pain intensity (VAS) and plasma concentration was more positive for oxycodone ( [Formula: see text] ). There was a positive relationship between morphine-6-glucuronide concentrations and urea nitrogen and creatinine levels ( [Formula: see text] ). Controlled-release oxycodone was as effective as controlled-release morphine in relieving chronic cancer-related pain, and as easily titrated to the individual's need for pain control. While adverse experiences were similar, controlled-release oxycodone was associated with less itching and no hallucinations. Controlled-release oxycodone provides a rational alternative to controlled-release morphine for the management of moderate to severe cancer-related pain.
OxyCon Game
Oxycontin use
Kadian v MS Contin
The Oxycontin Doctor
Oxycodone: structure
Oxycodone: metabolism
Oxycodone plus sertraline
Tramadol versus oxycodone
Oxycodone controlled-release
Oxycontin: politics and science
OxyContin: prescribing indications

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family